实用肿瘤杂志

参考文献

[1] Trepte ML, Auten JJ, Clark SM, et al. Dose-related mucositis with hydroxyurea for cytoreduction in acute myeloid leukemia[J]. J Oncol Pharm Pract, 2019, 25(4):801-805.

[2] R?llig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia?[J]. Blood, 2015, 125(21):3246-3252.

[3] Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis:a systematic review and meta-analysis[J]. Leuk Res, 2014, 38(4):460-468.

[4] Shallis RM, Stahl M, Bewersdorf JP, et al. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis:a contemporary appraisal of outcomes and benefits[J]. Expert Rev Hematol, 2020, 13(5):489-499.

[5] Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis:a review of pathophysiology, clinical presentation and management[J]. Leuk Lymphoma, 2000,39(1/2):1-18.

[6] Stone RM, DeAngelo DJ, Janosova A, et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission[J]. Am J Hematol, 2008, 83(10):771-777.

[7]王敏,王立茹,崔建英,等.高白细胞急性髓系白血病B细胞淋巴瘤因子2(BCL-2)的表达及临床意义[J].中国实验血液学杂志, 2013, 21(4):851-856.

[8] Ali AM, Mirrakhimov AE, Abboud CN, et al. Leukostasis in adult acute hyperleukocytic leukemia:a clinician's digest[J]. Hematol Oncol, 2016, 34(2):69-78.

[9] Yang YM, He HP, He JG, et al. Hyperleukocytic acute leukemia circulating exosomes regulate HSCs and BMMSCs[J]. J Healthc Eng, 2021, 2021:9457070.

[10] Ali AM, Mirrakhimov AE, Abboud CN, et al. Leukostasis in adult acute hyperleukocytic leukemia:a clinician's digest[J]. Hematol Oncol, 2016, 34(2):69-78.

[11] Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia:can a better understanding of the underlying molecular pathophysiology lead to novel treatments?[J]. Cells, 2020, 9(10):E2310.

[12] Bug G, Anargyrou K, Tonn T, et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis[J]. Transfusion, 2007,47(10):1843-1850.

[13] Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia:a single-center retrospective study and review of literature[J]. Leuk Res,2008, 32(8):1221-1227.

[14] Feng SL, Zhou L, Zhang XH, et al. Impact of ELN risk stratification, induction chemotherapy regimens and hematopoietic stem cell transplantation on outcomes in hyperleukocytic acute myeloid leukemia with initial white blood cell count more than 100×109/L[J]. Cancer Manag Res, 2019, 11:9495-9503.

[15] Tien FM, Hou HA, Tsai CH, et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients[J]. Eur J Haematol, 2018, 101(1):86-94.

[16] Lagunas-Rangel FA, Chávez-Valencia V. FLT3-ITD and its current role in acute myeloid leukaemia[J]. Med Oncol, 2017, 34(6):114.

[17] Rogers HJ, Hsi ED, Tang GL, et al. Most myeloid neoplasms with deletion of chromosome 16q are distinct from acute myeloid leukemia with inv(16)(p13.1q22):a bone marrow pathology group multicenter study[J]. Am J Clin Pathol, 2017, 147(4):411-419.

[18] D?hner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia[J].Blood, 2020, 135(5):371-380.

[19] Largeaud L, Bertoli S, Bérard E, et al. Genomic landscape of hyperleukocytic acute myeloid leukemia[J]. Blood Cancer J, 2022, 12(1):4.

[20] Naseem S, Binota J, Varma N, et al.NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia[J].Int J Hematol Oncol Stem Cell Res, 2021, 15(1):15-26.

[21] Mosquera Orgueira A, Bao Pérez L, Mosquera Torre A, et al. FLT3 inhibitors in the treatment of acute myeloid leukemia:current status and future perspectives[J]. Minerva Med, 2020, 111(5):427-442.

[22] Abe A, Yamamoto Y, Katsumi A, et al. Truncated RUNX1generated by the fusion of RUNX1 to antisense GRIK2 via a cryptic chromosome translocation enhances sensitivity to granulocyte colony-stimulating factor[J]. Cytogenet Genome Res, 2020, 160(5):255-263.

[23] Saia M, Termanini A, Rizzi N, et al. AML1/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem/progenitor cells[J]. Sci Rep, 2016, 6:34957.

[24] Studniak E, Maloney E, Ociepa T, et al. Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children[J]. Pol J Pathol, 2013, 64(2):121-128.

[25]康娅,王梦昌.五例白血病全外显子测序结果分析[J].实用肿瘤杂志, 2020, 35(4):336-340.

[26] Maritz MF, Napier CE, Wen VW, et al. Targeting telomerase in hematologic malignancy[J]. Future Oncol, 2010,6(5):769-789.

[27] Othman MAK, Vuji?D, Zecevi?Z, et al. A cryptic threeway translocation t(10;19;11)(p12.31;q13.31;q23.3)with a derivative Y-chromosome in an infant with acute myeloblastic leukemia(M5b)[J]. Gene, 2015, 563(2):115-119.

[28]王敏,王立茹.高白细胞白血病研究现状[J].中国实用内科杂志, 2011, 31(4):298-300.

[29]李昕权,范炜,阎安文,等.高白细胞性白血病患者细胞分离治疗及端粒酶检测[J].白血病, 2000, 9(6):338-340.

[30]李星,王立茹,崔建英,等.黏附分子CD56、CD44、CD54、CD11a在急性髓系白血病骨髓中的表达及意义[J].临床血液学杂志, 2015, 28(7):600-604.

[31] Spertini C, Ba?sse B, Bellone M, et al. Acute myeloid and lymphoblastic leukemia cell interactions with endothelial selectins:critical role of PSGL-1, CD44 and CD43[J].Cancers(Basel), 2019, 11(9):E1253.

[32]吴辉菁,陈燕.高白细胞性白血病的生物学特性研究[J].中国实验血液学杂志, 2006, 14(3):450-454.

[33] Angulo M, Machado D, Larrosa L, et al. Real and spurious hypoxemia in a patient with extreme hyperleukocytosis[J].Med Intensiva(Engl Ed), 2019, 43(7):435-436.

[34]杨婉玲,顾岩,付秀华.贝伐珠单抗胸腔灌注治疗肺腺癌伴恶性胸腔积液疗效与血清VEGF水平的关系[J].实用肿瘤杂志, 2021, 35(1):62-64.

[35]李学亮,徐永昌.高白细胞急性白血病患者血清VEGF及sICAM-1检测的临床意义[J].临床血液学杂志,2010, 23(9):527-529.

[36] Creutzig U, R?ssig C, Dworzak M, et al. Exchange transfusion And leukapheresis in pediatric patients with AML with high risk of early death by bleeding and leukostasis[J]. Pediatr Blood Cancer, 2016; 63(4):640-645.

[37]吴秀兰,李学亮.高白细胞急性白血病患者血清s ICAM-1表达研究[J].医学信息, 2011, 24(15):4974-4975.

[38]张秀莲,张伟华,范星火,等. LFA-1与ICAM-1在急性髓性高白细胞白血病中的表达[J].白血病·淋巴瘤,2006, 15(3):174-175.

[39] Récher C. Clinical implications of inflammation in acute myeloid leukemia[J]. Front Oncol, 2021, 11:623952.

[40] Korkmaz S. The management of hyperleukocytosis in2017:do we still need leukapheresis?[J]. Transfus Apher Sci, 2018, 57(1):4-7.

[41]胡瑜,郑波.急性高白细胞性白血病的临床研究进展[J].国际输血及血液学杂志, 2019, 42(6):535-542.

[42] Nan XY, Qin Q, Gentille C, et al. Leukapheresis reduces4-week mortality in acute myeloid leukemia patients with hyperleukocytosis-a retrospective study from a tertiary center[J]. Leuk Lymphoma, 2017, 58(9):1-11.

[43] Ngo RT, Webb McAdams AL, Furiato A. Acute myeloid leukemia complicated by hyperleukocytosis and leukostasis in the emergency department[J]. Cureus, 2021, 13(6):e15392.